Thyrocare Technologies Gears Up for Q3 Reveal on 28th January; Check Key Expectations Here

Thyrocare Technologies's Q3 results FY26 are scheduled to be announced on 28th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Thyrocare Technologies Q3 Results 2026 Preview

• Thyrocare Technologies' revenue is expected to be in the range of ₹165.92 crore, a 6.45% YoY decrease. 
• Profit After Tax, or PAT, is projected to fall by 28.37% YoY. 
• Thyrocare Technologies' EBITDA is expected to fall to ₹29.95 crore. 
• Net profit is ₹19.11 crore, a fall 28.37% YoY 

Thyrocare Technologies Share Performance 

• Over the past six months, Thyrocare Technologies' share price has fallen by 9.65% to ₹455.55.
• Moreover, over the past year, the stock has increased by 72.97%.
• Despite this weak short-term performance, Thyrocare Technologies' stock has delivered a financially sound 51.26% return over the past 5 years.
• As of 27th January 2026, the stock traded at ₹455.55 per share.

Key Factors to Watch for Thyrocare Technologies Q3 Results FY26 

• Revenue & test volume growth – Strength in topline growth driven by increased pathology and radiology tests, reflecting demand for diagnostic services.
• Profitability & margins – Trends in EBITDA, gross margin and net profit showing operational efficiency and cost control.
• Network expansion & franchise performance – Growth in labs, franchise partners and geographic reach boosting scale and service penetration.
• Asset quality & cash position – Debt-free status and healthy cash balances supporting financial stability and future investments.
• Strategic initiatives & acquisitions – Impact of recent acquisitions and technology upgrades on future growth and service diversification.

Final Thoughts

Thyrocare Technologies will announce its Q3 FY26 results on 28th January 2026. Analysts expect 6.45% YoY revenue growth, a 28.37% fall in PAT, and a 29.95% fall in EBITDA. Thyrocare Technologies focuses on: driving test-volume led growth through its asset-light diagnostic model while improving margins via scale, automation, and network expansion.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026

Best Stocks to Buy Today: Explore Best Stocks With Expected Trends

Milky Mist Dairy Foods IPO Details: Everything You Should Know about 

Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?

Taurian MPS IPO GMP & Review: Should You Apply or Avoid?

Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?

Dev Thyrocare Technologieselerator IPO GMP & Review: Apply or Avoid?

Vigor Plast India IPO Listing Preview: What to Expect Now?

Krupalu Metals IPO GMP: Day 3 IPO Live Updates